Aldose reductase inhibition decelerates optic nerve degeneration by alleviating retinal microglia activation

As part of the central nervous system (CNS), retinal ganglion cells (RGCs) and their axons are the only neurons in the retina that transmit visual signals from the eye to the brain via the optic nerve (ON). Unfortunately, they do not regenerate upon injury in mammals. In ON trauma, retinal microglia (RMG) become activated, inducing inflammatory responses and resulting in axon degeneration and RGC loss. Since aldose reductase (AR) is an inflammatory response mediator highly expressed in RMG, we investigated if pharmacological inhibition of AR can attenuate ocular inflammation and thereby promote RGC survival and axon regeneration after ON crush (ONC). In vitro, we discovered that Sorbinil, an AR inhibitor, attenuates BV2 microglia activation and migration in the lipopolysaccharide (LPS) and monocyte chemoattractant protein-1 (MCP-1) treatments. In vivo, Sorbinil suppressed ONC-induced Iba1 + microglia/macrophage infiltration in the retina and ON and promoted RGC survival. Moreover, Sorbinil restored RGC function and delayed axon degeneration one week after ONC. RNA sequencing data revealed that Sorbinil protects the retina from ONC-induced degeneration by suppressing inflammatory signaling. In summary, we report the first study demonstrating that AR inhibition transiently protects RGC and axon from degeneration, providing a potential therapeutic strategy for optic neuropathies.

Automated summary

Retinal ganglion cells (RGCs) and their axons are important for transmitting visual signals from the eye to the brain, but they cannot regenerate in mammals. In this study, researchers investigated the effects of inhibiting aldose reductase (AR), an inflammatory response mediator, on ocular inflammation and RGC survival after optic nerve crush (ONC). The results showed that AR inhibition attenuated inflammation, promoted RGC survival, and delayed axon degeneration, suggesting it as a potential therapeutic strategy for optic neuropathies.